Compare MTX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTX | ANIP |
|---|---|---|
| Founded | 1968 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1992 | N/A |
| Metric | MTX | ANIP |
|---|---|---|
| Price | $62.15 | $81.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $79.67 | ★ $105.83 |
| AVG Volume (30 Days) | 187.1K | ★ 386.7K |
| Earning Date | 02-05-2026 | 11-07-2025 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | ★ $2,071,200,000.00 | $826,880,000.00 |
| Revenue This Year | N/A | $44.06 |
| Revenue Next Year | $4.02 | $9.06 |
| P/E Ratio | ★ N/A | $49.20 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $49.54 | $52.74 |
| 52 Week High | $78.23 | $99.50 |
| Indicator | MTX | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 62.47 | 42.60 |
| Support Level | $60.37 | $80.27 |
| Resistance Level | $62.64 | $82.78 |
| Average True Range (ATR) | 1.38 | 2.25 |
| MACD | 0.08 | 0.26 |
| Stochastic Oscillator | 81.11 | 43.69 |
Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of its customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve its customers' manufacturing processes and projects. The majority of revenue comes from the United States.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.